- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06356103
Whey-Based Partially Hydrolyzed Formula Versus Polymeric Formula On Undernourished Neurologically Impaired Children: Open-labelled Randomized Study
August 16, 2024 updated by: Alexandria University
Purpose: Undernutrition is common in neurologically impaired children.
It increases the burden of comorbidities and affects the quality of life of these children.
This study aimed primarily to compare the efficacy of whey-based partially hydrolyzed formula (WPHF) versus isocaloric polymeric formula on the nutritional status reflected by growth parameters and feeding tolerance in undernourished children with neurological impairment (NI).
The secondary aim was to follow up on the changes in these parameters after using WPHF for 3 and 6 months
Study Overview
Status
Completed
Conditions
Detailed Description
This prospective open-label randomized study was conducted over 6 months on children with NI aged 2- 6 years.
Patients were divided into two groups: one group received 50% of their caloric requirements as isocaloric polymeric formula (standard ) and 50% standard nutritional feeding according to ESPGHAN guidelines (group I), the second group received 50% of their caloric requirements as WPHF, and the other 50% standard nutritional feeding according to ESPGHAN guidelines (group II).
At the start of the study, detailed clinical and nutritional history was recorded for all children in the two groups.
Anthropometric measurements were measured, and the Z score was calculated for all parameters.
Symptoms of feeding intolerance and frequency of chest infections were assessed and reported.
These parameters were reassessed after 3 months and 6 months of nutritional intervention and compared between the two groups.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alexandria, Egypt, 23445
- Alexandria University Children Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Children aged from 2-6 years
undernourished children with NI (1 or more of the following signs for identification of undernutrition in the studied children:
- weight for age z score <-2,
- triceps skinfold thickness <10th centile for age,
- mid-upper arm fat or muscle area <10th percentile for age,
- faltering weight
- failure to thrive.
- physical signs of undernutrition such as decubitus skin problems and poor peripheral circulation
Exclusion Criteria:
- NI due to metabolic diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group I
received 50% of their caloric requirements as isocaloric polymeric formula (standard ) and 50% standard nutritional feeding according to ESPGHAN guidelines
|
protein and micronutrient requirements according to the recommended dietary allowance (RDA)
|
|
Active Comparator: Group II
received 50% of their caloric requirements as WPHF and the other 50% as standard nutritional feeding
|
Peptamen junior, 100 kcal/100 ml (Nestlé Health Science, Vevey, Switzerland).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To compare the efficacy of whey-based partially hydrolyzed formula versus standard feeding on the weight in kilogram in undernourished children with neurological impairment (NI).
Time Frame: 6 months
|
Identify the Efficacy Of Whey-Based Partially Hydrolyzed Formula on the weight in Kilogram measured using the double weighing method (weight of the parent subtracted from the combined weight of parent and child) on a digital scale.
|
6 months
|
|
To compare the efficacy of whey-based partially hydrolyzed formula versus standard feeding on the height/length in centimeter in undernourished children with neurological impairment (NI).
Time Frame: 6 months
|
Identify the Efficacy Of Whey-Based Partially Hydrolyzed Formula on the height/length in Centimeter measured by a stadiometer.
In children with joint contractions, spasticity, and/or scoliosis, the length was measured by segmental length measurements using sliding calipers.
Then the length was estimated by simple equations such as knee-heel length (L = (2.69
x KH) + 24.2), tibia length (L = (3.26
x TL) + 30.8).
|
6 months
|
|
To compare the efficacy of whey-based partially hydrolyzed formula versus standard feeding on the body mass index (BMI) in children with neurological impairment (NI).
Time Frame: 6 months
|
Identify the Efficacy Of Whey-Based Partially Hydrolyzed Formula on the body mass index (BMI) calculated as [weight in kg]/ [height in m]2
|
6 months
|
|
To compare the efficacy of whey-based partially hydrolyzed formula versus standard feeding on the head circumference in centimeter in undernourished children with neurological impairment (NI)
Time Frame: 6 months
|
Identify the Efficacy Of Whey-Based Partially Hydrolyzed Formula on the head circumference (HC) in Centimeter measured by non-stretchable tape
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To follow up the efficacy of whey-based partially hydrolyzed formula versus standard feeding on the weight in kilogram in undernourished children with neurological impairment (NI) for 3 and 6 months
Time Frame: 6 months
|
Follow up the Efficacy Of Whey-Based Partially Hydrolyzed Formula on the weight in Kilogram measured using the double weighing method (weight of the parent subtracted from the combined weight of parent and child) on a digital scale for 3 and 6 months
|
6 months
|
|
To follow up the efficacy of whey-based partially hydrolyzed formula versus standard feeding on the height/length in Centimeter in undernourished children with neurological impairment (NI) for 3 and 6 months
Time Frame: 6 months
|
Follow up the Efficacy Of Whey-Based Partially Hydrolyzed Formula on the height/length in Centimeter measured by a stadiometer.
In children with joint contractions, spasticity, and/or scoliosis, the length was measured by segmental length measurements using sliding calipers.
Then, the length was estimated by simple equations such as knee-heel length (L = (2.69
x KH) + 24.2), tibia length (L = (3.26
x TL) + 30.8) for 3 and 6 months.
|
6 months
|
|
To follow up the efficacy of whey-based partially hydrolyzed formula versus on the body mass index in undernourished children with neurological impairment (NI) for 3 and 6 months
Time Frame: 6 months
|
Follow up the Efficacy Of Whey-Based Partially Hydrolyzed Formula on the body mass index (BMI) calculated as [weight in kg]/ [height in m]2 for 3 and 6 months
|
6 months
|
|
To follow up the efficacy of whey-based partially hydrolyzed formula versus standard feeding on the head circumference in Centimeter in undernourished children with neurological impairment (NI) for 3 and 6 months
Time Frame: 6 months
|
Follow up the Efficacy Of Whey-Based Partially Hydrolyzed Formula on the head circumference (HC) in Centimeter measured by non-stretchable tape for 3 and 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2022
Primary Completion (Actual)
December 31, 2022
Study Completion (Actual)
July 15, 2023
Study Registration Dates
First Submitted
March 16, 2024
First Submitted That Met QC Criteria
April 2, 2024
First Posted (Actual)
April 10, 2024
Study Record Updates
Last Update Posted (Actual)
August 19, 2024
Last Update Submitted That Met QC Criteria
August 16, 2024
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0107060
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurologic Disorder
-
Abant Izzet Baysal UniversityNot yet recruiting
-
Fondation Ellen PoidatzRecruiting
-
Chung-Ang University Gwangmyeong HospitalNot yet recruitingNeurologic Disorder
-
Medical University of ViennaNeurologisches Rehabiliationszentrum RosenhügelRecruitingNeurologic DisorderAustria
-
Rehabilitation Hospital of Overland ParkDiscovery StatisticsRecruitingNeurologic DisorderUnited States
-
Wake Forest University Health SciencesIndiana University; Norton Healthcare; Child Neurology FoundationCompletedNeurologic DisorderUnited States
-
University Hospital, ToulouseIpsenCompleted
-
Henri Mondor University HospitalNot yet recruiting
-
Pôle Saint HélierINSA RennesCompleted
-
NHS LothianCompleted